Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 401–500 of 1,639
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 14
Self-citationLewis, A., Dodd, M. S., Sourdon, J., Lygate, C. A., Clarke, K., Neubauer, S., Tyler, D. J., & Rider, O. J. (2024) · NMR in Biomedicine · doi:10.1002/nbm.5206 · Cited by 11
Ketema, E. B., & Lopaschuk, G. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.01.029 · Cited by 19
Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans
Liu, X., Lu, C. A., Shih, Y.-C. T., & Jiang, C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.29842 · Cited by 12
Tackling metabolic defects in HFpEF
Wang, R., & Schiattarella, G. G. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad884 · Cited by 14
Semaglutide and Exercise Function in Obesity-Related HFpEF
Borlaug, B. A., Kitzman, D. W., Patel, S., Chinnakondepalli, K., Butler, J., Davies, M. J., Petrie, M. C., Shah, S. J., Verma, S., Núñez, J. E., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102660 · Cited by 16
Self-citationSemaglutide and heart failure: Updated meta-analysis.
Barbagelata, L., Masson, W. M., Lobo, M., & Bluro, I. M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102721 · Cited by 13
Cardiometabolic Dysregulation and Heart Failure
Ashfield, S., & Ojha, U. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm38504 · Cited by 15
“[31] demonstrated that semaglutide, in comparison to placebo, leads to greater weight loss, reduction in symptoms and improved exercise capacity.”
Shahid, I., Khan, M. S., Butler, J., Fonarow, G. C., & Greene, S. J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10481-7 · Cited by 16
“…≥ 30 kg/m [2]), the glucagon-like peptide-1 (GLP-1) receptor agonist sema-glutide and dual GLP-1 and glucagon insulinotropic peptide (GIP) agaonost terzepatide are proven to substantially improve patient-reported symptoms and functional limitations, and to cause significant weight loss [36, 37].”
Self-citationNew pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., Klingenberg, R., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf012 · Cited by 18
Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis
Masson, W. M., Lobo, M., Barbagelata, L., Cobo, A. L., & Nogueira, J. P. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.01.001 · Cited by 26
Medically Tailored Meals in Heart Failure: A Systematic Review of the Literature, 2013-2023
McIntosh, N. M., Billingsley, H., Hummel, S. L., & Mills, W. L. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.10.446 · Cited by 14
Qi, Z., Wu, D., Yan, Z., Wang, Q., Li, Y., Zhao, J., & Xu, F. (2025) · Obesity Reviews · doi:10.1111/obr.13912 · Cited by 16
“…adipose tissue inflammation and adipocyte hypertrophy, and improves myocardial hypertrophy [150 – 152] Improve abnormal diastolic function [153] Increased glucose uptake, decreased secretion of pro-inflammatory chemokines [158] Activating the NO-cGMP-PKG pathway [160] Reduce EAT thickness…”
Semaglutide for adults living with obesity
Bracchiglione, J., Meza, N., Franco, J. V. A., Liquitay, C. M. E., Victoria Novik, A., Vargas, M. O., Lazcano, G., Poloni, D., Langlotz, F. R., Figuls, M. R. I., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015092.pub2 · Cited by 36
Lee, G. A., Durante, A., Baker, E. E., Vellone, E., Caggianelli, G., Dellafiore, F., Khan, M., & Khatib, R. (2024) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvae081 · Cited by 12
Glucagon-like peptide-1 receptor agonism and end-organ protection
Daniels, S. J., Karlsson, C., Schrauwen, P., & Parker, V. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.01.002 · Cited by 20
Bansal, B., Lajeunesse‐Trempe, F., Keshvani, N., Lavie, C. J., & Pandey, A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.04.012 · Cited by 28
Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights
Sarkar, A., Fanous, K., Marei, I., Ding, H., Ladjimi, M. M., MacDonald, R. S., Hollenberg, M. D., Anderson, T. J., Hill, M. A., & Triggle, C. R. (2024) · Vascular Health and Risk Management · doi:10.2147/vhrm.s391808 · Cited by 11
Gonzales-Uribe, A., Ruiz-Cortez, R., Silva, N. C., Olivero, L. J., Agarwal, R., Castillo, S. A., Garcia-Geng, A., Lyu, X., Mendoza‐Quispe, D., Becerra-Gonzales, V. G., et al. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02710-8 · Cited by 15
“Among these, five were multicenter studies [14, 15, 22–24], while one was conducted at a single center by Wallner et al ., 2024 [25].”
InfluentialBalestrieri, G., Limonta, R., Ponti, E., Merlo, A., Sciatti, E., D’Isa, S., Gori, M., Casu, G., Giannattasio, C., Senni, M., et al. (2024) · Cardiac failure review · doi:10.15420/cfr.2023.13 · Cited by 16
“26 Current Progress in ‘Phenomapping’: Insights From the Literature Recently, a review conducted by Peters et al. identified the three most recurrent HFpEF phenotypes in studies that focused on specific characteristics through statistical analysis of large datasets, known as ‘phenomapping’.”
Self-citationBabazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
“…Effects in People with Obesity (STEP) program, found that 2.4 mg semaglutide in combination with lifestyle modifications had clinically significant weight loss between 9.6% and 16.0% compared with placebo [6 – 14]; FDA approved semaglutide (Wegovy) for the treatment of obesity in 2021 [15].”
InfluentialAllahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
The Impact of Obesity on Cardiovascular Diseases: Heart Failure
Alansari, H., Lazzara, G. E., Taha, M. B., & Gorthi, J. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1511 · Cited by 18
Ahmed, M., Burhan, M., Shafiq, A., Hashmi, T. M., Ahmed, R., Fudim, M., Mentz, R. J., & Fonarow, G. C. (2025) · Clinical Cardiology · doi:10.1002/clc.70234 · Cited by 12
Effect of GLP1 Agonists on Reproduction
Couldwell, M., Tidwell, A. J., & Taylor, A. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf401 · Cited by 16
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
Pack, A. I., Grunstein, R. R., Mokhlesi, B., Ryan, S., Schwab, R., & Gozal, D. (2025) · SLEEP · doi:10.1093/sleep/zsaf045 · Cited by 14
Age-Stratified Profiles and Outcomes of Patients with Heart Failure with Preserved Ejection Fraction
Yamanaka, S., Nochioka, K., Hayashi, H., Shiroto, T., Takahashi, J. A., Miyata, S., Yasuda, S., Shimokawa, H., & the CHART-2 Investigators (2024) · ESC Heart Failure · doi:10.1002/ehf2.14798 · Cited by 13
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 23
Kidney Disease and Heart Failure: Recent Advances and Current Challenges
Lam, C. S. P., Bozkurt, B., Cherney, D. Z. I., Ezekowitz, J. A., Jardine, M., Khan, S. S., Madero, M., Sarnak, M. J., ter Maaten, J. M., Cheung, M., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.102943 · Cited by 21
“88 Similar to HFrEF, GDMT for HFpEF has not been well studied in patients with advanced CKD, including those with kidney failure treated with dialysis or kidney transplantation.”
Self-citationInsights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 15
Sequeira, V., Theisen, J., Ermer, K. J., Oertel, M., Xu, A., Weissman, D., Ecker, K., Dudek, J., Faßnacht, M., Nickel, A. G., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15152 · Cited by 14
“2 In patients with HFpEF, obesity exacerbates symptoms of HF without substantially affecting mortality.”
InfluentialOstrominski, J. W., & Powell‐Wiley, T. M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01182-3 · Cited by 15
“…Ejection Fraction), semaglutide (2.4 mg) substantially improved HF-related symptoms, weight, exercise function, systemic inflammation, and natriuretic peptides as compared to placebo among 529 adults without T2D, BMI ≥ 30 kg/m 2 , and HF with left ventricular ejection fraction ≥ 45% [77].”
InfluentialPhysiologic Phenotyping of Responses to Exercise and Activity in Heart Failure
Lewis, G. D., Tada, A., Landsteiner, I., & Borlaug, B. A. (2025) · Circulation Research · doi:10.1161/circresaha.125.325534 · Cited by 18
Self-citationHarrington, J., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Lingvay, I., Pagidipati, N. J., Sattar, N. A., Spall, H. G. C. V., Verma, S., & McGuire, D. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-023-02016-z · Cited by 12
Self-citationGLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
“Semaglu-tide improved heart failure–related symptoms and physical limitation measured by the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-CSS), exercise function measured by 6-minute walking distance, and reduced inflammation and body weight (93).”
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Harrington, J., Gale, S. E., & Vest, A. R. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011518 · Cited by 11
Whitman, J., Kozaily, E., Michos, E. D., Silverman, D. N., Fudim, M., Mentz, R. J., Tedford, R. J., & Rao, V. N. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00700-5 · Cited by 15
“Incretin-based treatments such as GLP-1a are approved for the treatment of type 2 diabetes and obesity and associated cardiovascular outcomes [83–86].”
Wang, T., Yang, Q., Cheng, X.-Y., Ding, J.-C., & Hu, P.-F. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10438-2 · Cited by 14
“…to week 52, the mean change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) was 16.6 points in the semaglutide group and 8.7 points in the placebo group, and the mean change in body weight in the semaglutide group was − 13.3% and − 2.6% in the placebo group [51].”
InfluentialCardiovascular-Kidney-Metabolic (CKM) Syndrome: A Case-Based Narrative Review
Javaid, A., Hariri, E. H., Özkan, B., Lang, K., Khan, S. S., Rangaswami, J., Stone, N. J., Blumenthal, R. S., & Ndumele, C. E. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100089 · Cited by 15
“Additionally, although there is growing data about the benefits of GLP-1RA in HFpEF, 33 and the SELECT trial indicated significant cardiovascular risk reduction in the subgroup with heart failure, there is not yet definitive data regarding their primary utilization as foundational therapy in HFrEF.”
Chiang, C., Chang, Y., Yu, C.-C., See, X. Y., Wang, T. H., Xanthavanij, N., Song, J., Lo, S., Chiang, C.-H., Lake, L. L., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.020 · Cited by 15
Retatrutide: A Triple Incretin Receptor Agonist for Obesity Management
Ray, A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2276754 · Cited by 11
“…symptoms, physical limitations, and exercise function among patients with heart failure with pre-served ejection fraction in the STEP-HFpEF trial [50], there is a growing interest to understand if the increasing portfolio of obesity medicines could be beneficial in the management of heart…”
BackgroundRavikulan, R., Chavali, S., Gunton, J. E., & Pasquale, C. G. D. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70085 · Cited by 15
Obesity as a risk factor in atrial fibrillation and heart failure
Jurica, J., Péč, M. J., Benko, J., Bolek, T., Galajda, P., Mokáň, M., & Samoš, M. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01332-z · Cited by 13
“Although the study was underpowered for the assessment of clinical end-points (only 13 HF-related events occurred during study follow-up), there was a trend towards lower incidence of these events in semaglutide-treated patients [64].”
ResultBauersachs, J. K., Kato, E. T., & Rangaswami, J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15345 · Cited by 12
“…an eGFR 30 mL/min/1.73 m 2 and HF. 58,59 While subgroup analyses are available from CKD (including analyses of participants with HF) and HF trials (including analyses of participants with CKD), 53,60 – 75 they are often exploratory and insuf fi ciently powered with respect to ef fi cacy outcomes.”
InfluentialIncretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
Dreher, L., Kylies, D., Danser, A. H. J., & Wenzel, U. O. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25112 · Cited by 13
Bonacchi, G., Rossi, V. A., Garofalo, M., Mollace, R., Uccello, G., Pieragnoli, P., Checchi, L., Perrotta, L., Voltolini, L., Ricciardi, G., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12050981 · Cited by 14
“This has been the case for the GLP1 receptor antagonist semaglutide, which showed symptom and functional improvement in patients with HFpEF and obesity [130].”
BackgroundAradhyula, V., Vyas, R., Dube, P. R., Haller, S. T., Gupta, R., Maddipati, K. R., Kennedy, D. J., & Khouri, S. J. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00068.2024 · Cited by 14
Müller, M., Schubert, T., Welke, C., Maske, T., Patschkowski, T., Donhauser, E., Heinen‐Weiler, J., Hormann, F.-L., Heiles, S., Schulz, T. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59192-5 · Cited by 14
“Despite the promising effects of SGLT2 inhibitors in HFpEF patients 5 and the impressive effects of GLP-1 agonists on symptom burden in obese HFpEF 62 , more treatment options arewarranted for thishighly prevalent and morbiddisorder,especially considering the limited tolerability to GLP-1 agonists…”
Glycometabolic cardiac dysfunction in HFpEF: Lessons from multi-omics studies
Longo, S., Mollace, R., Casagrande, V., Bucciarelli, L. G., Martelli, E., Menghini, R., Fernández‐Real, J. M., & Federici, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108032 · Cited by 11
López-Jiménez, F. A., Cesare, M. D., Powis, J., Shrikhande, S. S., Adeoye, M., Codato, E., Zhou, B., Bixby, H., Evans, N. R., Lara-Breitinger, K. M., et al. (2025) · Global Heart · doi:10.5334/gh.1451 · Cited by 19
Habel, N., Infeld, M. M., Lustgarten, D. L., & Meyer, M. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.08.064 · Cited by 16
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 29
“In patients with obesity and HFpEF, treatment with semaglutide led to improvement in symptoms, physical limitations, and exercise capacity (144).”
McVay, M. A., Moore, W. S., Wilkins, F. L., Jackson, J. R., & Robinson, M. D. (2024) · Obesity Science & Practice · doi:10.1002/osp4.783 · Cited by 10
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
“Obesity-related diseases and conditions that benefit from this weight-loss magnitude include metabolic dysfunction–associated steatohepatitis with moderate- to-severe fibrosis, 7 46 heart failure with preserved ejection fraction, 47 48 and knee osteoarthritis.”
Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure
Dhore-Patil, A., Urina‐Jassir, D., Samson, R., Jemtel, T. H. L., & Oparil, S. (2024) · Current Hypertension Reports · doi:10.1007/s11906-024-01302-7 · Cited by 13
“A randomized, placebo-controlled trial recently reported that 52 weeks with 2.4 mg of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP1-RA), significantly improved HF-related symptoms and physical limitations in patients with HFpEF and a median BMI of 37.2 kg/m 2 [75].”
BackgroundInfluentialMultimodal, device-based therapeutic targeting of the cardiovascular autonomic nervous system
Paton, J. F. R., Żera, T., Vadigepalli, R., Herring, N., & Paterson, D. J. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01212-4 · Cited by 20
Managing Obesity in Heart Failure
Harrington, J., Felker, G. M., Lingvay, I., Pagidipati, N. J., Pandey, A., & McGuire, D. K. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.09.005 · Cited by 13
Focusing on microvascular function in heart failure with preserved ejection fraction
Velollari, O., Rommel, K., Kresoja, K., Lurz, P. C., & Gori, T. (2025) · Heart Failure Reviews · doi:10.1007/s10741-024-10479-7 · Cited by 15
“Among others, these mostly include pharmacotherapy comprising SGLT-2 inhibitors and/or mineral corticoid receptor antagonists, which improve quality of life and reduce hospitalization [9, 51].”
New and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 14
“%) and obesity (body mass index (BMI) ≥ 30)) 107 and the STEP-HFpEF DM trial (616 individuals with HFpEF (EF ≥ 45%), obesity (BMI ≥ 30) and type 2 diabetes mellitus) 108 , individuals randomized to semaglutide demonstrated a significant improvement in symptoms and physical limitations as well as…”
Timóteo, A. T., de Albuquerque, F. B., & Teixeira, B. L. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132303 · Cited by 16
Targeting obesity for therapeutic intervention in heart failure patients
Sato, R., & von Haehling, S. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2363395 · Cited by 10
“…refer to the need for body weight management as limited to the prevention of new-onset HF [13,15], whereas it has recently been reported that the weight loss with glucagon-like peptide 1 (GLP-1) analogue has improved various aspects of HF-related clinical outcomes in obese HFpEF patients [16].”
BackgroundWester, M., Arzt, M. E., Sinha, F., Maier, L. S., & Lebek, S. (2023) · Biomedicines · doi:10.3390/biomedicines11113038 · Cited by 10
“These drugs have been shown to effectively reduce body weight and blood glucose levels [56,57].”
BackgroundThe evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“With a mean placebo-subtracted weight loss of 10–15% in people with obesity 12–14 , semaglutide set a benchmark for efficacy, helped to transform obesity care and demonstrated health benefits beyond obesity 13,15–17 .”
Zhang, Z., Xiao, Y., Dai, Y., Lin, Q., & Liu, Q. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10366-7 · Cited by 14
“However, emerging data from the STEP-HFpEF trial underscores the notable advantages of glucagon-like peptide-1 receptor agonists for obese HFpEF patients, especially in enhancing their quality of life [32].”
BackgroundMuscle health in the modern era of incretin‐based therapies
Girolamo, G. D., Sangineto, M., Gioia, G. D., Bianco, R., Ciarnelli, M., & Serviddio, G. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70155 · Cited by 16
“38 In addition, liraglutide has been associated with reduced thigh muscle fat in a randomized trial in a cohort of mostly women with overweight or obesity in the absence of diabetes, improving muscle quality rather than volume.”
Temporelli, P. L. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae011 · Cited by 13
“8 However, it is not known whether these benefits of semaglutide in STEP-HFpEF vary depending on the degree of health status impairment at baseline.”
BackgroundCurrent and Emerging Therapeutic Approaches for Vascular Cognitive Impairment and Dementia
Goodall, L., Lennon, M. J., Sachdev, P. S., Gorelick, P. B., Kovacic, J. C., & Samaras, K. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1502 · Cited by 17
Lee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00279-4 · Cited by 10
“These findings were similar to the PIONEER 6 study (Peptide Innovation for Early Diabetes Treatment) with oral semaglutide [74].”
BackgroundResultHeart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon
Lucà, F., Oliva, F. G., Abrignani, M. G., Fusco, S. A. D., Gori, M., Giubilato, S., Ceravolo, R., Temporelli, P. L., Cornara, S., Rao, C. M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051375 · Cited by 16
Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
Basile, L., Cannarella, R., Iuliano, S., Calogero, A. E., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04103-9 · Cited by 11
Lam, C. S. P., Bozkurt, B., Cherney, D. Z. I., Ezekowitz, J. A., Jardine, M., Khan, S. S., Madero, M., Sarnak, M. J., ter Maaten, J. M., Cheung, M., et al. (2026) · Kidney International · doi:10.1016/j.kint.2025.10.011 · Cited by 16
Self-citationEvaluating the safety profile of semaglutide: an updated meta-analysis
Rivera, F. B., Arias-Aguirre, E., Aguirre, Z., Ybañez, M. J. C., Rubia, J. M. M., Galang, D. J. C., Lumbang, G. N. O., Ruyeras, J. M. M., Magalong, J. V., Pine, P. L. S., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2383731 · Cited by 14
Liu, Y., Li, Z., Xu, X., Zou, Y., Zhang, M., Chen, Y., Zhu, W., & Han, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1529652 · Cited by 11
“Patients suffering from obesity and heartfailure who have preserved ejection fractionfare betterwhengiven semaglutide, according to the STEP-HFpEF trial (Borlaug et al., 2023; Kosiborod et al., 2023; Borlaug et al., 2023; Kosiborod et al., 2023).”
Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
Turkistani, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1535134 · Cited by 10
Aa, B., Serova, M., Chashkina, M. I., Kosharnaia, R. S., Salpagarova, Z. K., Andreev, D. A., & Giverts, I. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.06 · Cited by 13
Jiang, H., Wattanachayakul, P., Kittipibul, V., Nicolsen, E., McVeigh, T., Kamneva, O., & Fudim, M. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15308 · Cited by 11
“1,2 However, their bene-fi ts in patients other HFpEF phenotypes or heart failure with reduced ejection fraction (HFrEF) are less clear.”
Current Treatment of Heart Failure with Preserved Ejection Fraction
Riccardi, M., D’Elia, E., Lombardi, C., Savarese, G., Gori, M., Oliva, F. G., Volterrani, M., Senni, M., Metra, M., & Inciardi, R. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155406 · Cited by 13
Self-citationGlucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Faruque, L. I., Yau, K., & Cherney, D. Z. I. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001066 · Cited by 12
Khalil, I., Islam, M. R., Kamrul-Hasan, A. B. M., Nagendra, L., Promi, S. A., Sayed, M. A., Rahman, M. A., Sultana, N., Tasmi, N. A., Das, M., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.005 · Cited by 13
Recent advances associated with cardiometabolic remodeling in diabetes-induced heart failure
Sharma, G., Chaurasia, S. S., Carlson, M. A., & Mishra, P. K. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00539.2024 · Cited by 13
Weiskirchen, R., & Lonardo, A. (2025) · Medical Sciences · doi:10.3390/medsci13040265 · Cited by 22
“…MACE by 20% and slowing the progression of CKD among non-diabetic overweight or obese individuals with preexisting CV. Additionally, semaglutide improved the symptomatology of heart failure reducing hospital admission among individuals living with obesity regardless of their T2D status [83].”
Kondo, T., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., BRINKER, M. D., Lay‐Flurrie, J., Schloemer, P., Viswanathan, P., Amarante, F., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3669 · Cited by 11
Self-citationGlucagon-Like Peptide-1 Receptor Agonists in Heart Failure
Vaduganathan, M., & Ostrominski, J. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.09.812 · Cited by 10
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
Kaplan, J. M., Zaman, A., & Abushamat, L. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02097-4 · Cited by 12
“Again, while this effect may be due to the degree of weight lost, weight-independent effects, such as a decrease in N-terminal pro-B-type natriuretic peptide (NTproBNP) and hsCRP, were also observed suggesting an effect on hemodynamic status and inflammation [62].”
Bhattarai, N., & Scott, I. (2024) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2024.102461 · Cited by 10
Reddy, Y. N. V., Asokan, A. K., Frantz, R. P., Hemnes, A. R., Hassoun, P. M., Barnard, J., Horn, E. M., Leopold, J. A., Rischard, F. P., Rosenzweig, E. B., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202501-0034oc · Cited by 11
Self-citationRivera, F. B., Bantayan, N. R. B., Aparece, J. P., Cruz, L. L. A., Magallong, J. V., Pine, P. L. S., Idian, A. M. N., Lumbang, G. N. O., Lerma, E. V., Lara-Breitinger, K. M., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.03.011 · Cited by 10
Sklepinski, S. M., Deng, Y., SWARNA, K. S., Herrin, J. S., Polley, E. C., Neumiller, J. J., Galindo, R. J., Umpierrez, G. E., Ross, J. S., Borah, B. J., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112910 · Cited by 9
Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Odigwe, C. I., Mulyala, R. R., Malik, H., Ruiz, B., Riad, M., Sayiadeh, M. A., Honganur, S., Parks, A., Rahman, M. U., & Lakkis, N. M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100518 · Cited by 17
“Given this potent effect on weight reduction, Semaglutide was studied in 2 randomized control trials for clinical outcomes in both diabetics and nondiabetics with obesity and HFpEF [25 – 27].”
Yang, M., Kondo, T., Dewan, P., Desai, A. S., Lam, C. S. P., Lefkowitz, M. P., Packer, M., Rouleau, J. L., Vaduganathan, M., Zile, M. R., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011598 · Cited by 14
“31,32”
Ala, M., & Aleaba, M. M. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02459-3 · Cited by 12
Tran, B. A., White, R. T., Bullers, K., & Cornelio, C. K. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241261040 · Cited by 9
“27 Owing to loss of funding, the intended follow-up duration was shortened, potentially impacting the ability to capture a significant number of events.”
Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF
Doiron, J. E., Elbatreek, M. H., Xia, H., Yu, X., Gehred, N., Gromova, T., Chen, J., Driver, I. H., Muraoka, N., Jensen, M. B., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.011 · Cited by 12
Self-citationNguyen, A., Smith, E., Hashemy, H., Agarwal, S. M., Hahn, M., Paterson, A. D., & Dash, S. (2024) · Clinical Obesity · doi:10.1111/cob.12676 · Cited by 11
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf065 · Cited by 8
Menopause, epicardial adiposity and preserved ejection fraction heart failure
Museedi, A. S., Samson, R., & Jemtel, T. H. L. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132478 · Cited by 11
The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review
Biondi, F., & Madonna, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082705 · Cited by 12
“HFpEF has been specifically addressed by four specific large randomized controlled trials that have shown improvements in quality of life [22,23], HF hospitalization [21], and major adverse cardiovascular events [39].”
Influence of Trp-Cage on the Function and Stability of GLP-1R Agonist Exenatide Derivatives
Horváth, D., Stráner, P., Taricska, N., Fazekas, Z., Menyhárd, D. K., & Perczel, A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01553 · Cited by 13
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
Александровна, П. В., & Okovityi, S. V. (2026) · Biomedicines · doi:10.3390/biomedicines14040909 · Cited by 10
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.